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NEW ALZHEIMER'S DRUG UNDER STUDY 
Boston, Mass.--Researchers at Boston University School of Medicine (BUSM) 
and the University Hospital (UH) are p a r t i c i p a t i n g i n a nationwide, 
multicenter c l i n i c a l t r i a l of nimodipine, a drug that may not only slow the 
progression of Alzheimer's disease, but also represents a new approach to the 
treatment of t h i s disease. 
Alzheimer's disease, which affects an estimated four m i l l i o n Americans, i s 
a degenerative, neurological disorder characterized by progressive 
deterioration of i n t e l l e c t u a l , memory, language and behavioral functioning 
that ultimately leads to t o t a l d e b i l i t a t i o n . The brains of Alzheimer's 
patients have been found to be atrophied and deficient i n certain 
neurotransmitters--particularly acetylcholine--and also contain excessive 
amounts of calcium. 
T r a d i t i o n a l l y , the goal of treatment has been to improve the patient's 
functioning by attacking the symptoms. Drugs have primarily been used to 
replace the most commonly missing neurotransmitter--acetylcholine--which 
researchers believe may a f f e c t memory and language. 
Nimodipine, on the otfier hand, i s the f i r s t drug under study that 
p o t e n t i a l l y could slow the progression of the disease. A calcium blocker, 
nimodipine prevents excessive calcium--thought to contribute to brain c e l l 
death--from entering the cerebral blood vessels and being deposited i n the 
brain c e l l s . 
The current double-blind study w i l l involve 40 medical centers and nearly 
1500 patients considered mildly to moderately i l l . Patients receive 
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baseline tests for memory, language and behavior before taking nimodipine or a 
placebo and are retested a f t e r 26 weeks. 
" I believe the study i s large enough and designed well enough to answer 
the questions we have about nimodipine's a b i l i t y to slow the disease process. 
I f the results are positive and s i g n i f i c a n t , nimodipine could be an important 
breakthrough i n the treatment of t h i s devastating i l l n e s s , " says Sanford 
Auerbach, M.D., a neurologist at UH and an assistant professor of neurology at 
BUSM, who is conducting the t r i a l s . 
The University Hospital, founded i n 1855, i s a pri n c i p a l teaching hospital 
of Boston University School of I^dicine and a member of Boston University 
Medical Center. 
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